The supplement industry spent years fighting for legitimacy. Now it's fighting over valuations. Three separate acquisitions crossed or approached the billion-dollar mark in 2026 alone, and the pattern is clear: supplements have matured from a niche wellness category into a strategic asset class that CPG giants, private equity, and Asian conglomerates are all competing to own.
If you're building or operating a supplement brand today, this consolidation wave isn't background noise. It's rewriting the rules on what makes a business worth acquiring and what gets left behind.
P&G's $3.8 Billion Thorne Bet Is About Data, Not Just Products
Procter and Gamble's acquisition of Thorne HealthTech for $3.8 billion stands as the defining deal of this cycle. The price represents a dramatic step-up from Thorne's 2023 valuation and signals something specific: P&G wasn't buying a supplement catalog. It was buying clinical credibility and a direct-to-consumer data infrastructure that most legacy consumer goods companies can't build fast enough organically.
Thorne built its positioning around third-party testing, NSF certification, and partnerships with professional sports organizations. That clinical rigor translated into consumer trust, premium pricing power, and a subscriber base with measurable lifetime value. For P&G, those data assets are worth more than any single SKU.
The lesson for independent brands is uncomfortable but useful: revenue without clinical substantiation is a commodity. Acquirers are paying premium multiples for brands that can prove efficacy claims hold up, not just brands that sell well on Amazon.
Nestlé's $1 Billion Exit Tells the Other Half of the Story
While P&G moved in, Nestlé moved out. The Swiss food giant divested seven mainstream supplement brands, including Nature's Bounty, to private equity firm Yellow Wood Partners for approximately $1 billion. That transaction reflects a strategic reckoning playing out across legacy food companies that loaded up on supplement assets during the pandemic boom and are now trimming what doesn't fit their core identity.
Nestlé's exit isn't a vote of no confidence in supplements broadly. It's a vote of no confidence in undifferentiated, mass-market supplement products that compete on price and retail shelf space. The brands that got sold were largely commodity vitamin lines. The brands getting acquired at premium multiples, like Thorne, are anything but commodity.
This bifurcation matters. The supplement market is effectively splitting into two tiers: clinically positioned, data-rich brands that attract strategic buyers at high multiples, and volume-driven mass brands that trade hands between private equity at more modest valuations. If you're building in the middle, you're building in the most dangerous position in the market.
Bain Capital and Vitabiotics: Private Equity Sees Recurring Cash Flows
Bain Capital's acquisition of Vitabiotics for approximately $1.2 billion adds a third major deal to a cluster that is hard to dismiss as coincidence. Vitabiotics, the UK-based company behind brands like Wellwoman and Pregnacare, generates consistent, subscription-adjacent revenue from consumers who repurchase month after month. That predictability is exactly what private equity looks for when it's sizing up defensible cash flows.
The Vitabiotics deal also extends the geographic scope of this consolidation wave into the UK and European markets. For brands operating across those regions, the signal is the same: scale, category focus, and consumer loyalty data are the variables that determine whether you're on an acquirer's shortlist or not.
This is consistent with broader patterns in adjacent categories. As the fitness equipment market races toward $19.5 billion by 2030, the brands winning institutional attention share the same profile: defensible recurring revenue, proprietary data, and a clear consumer segment they own. Supplements are following the same script.
Kirin's Jamieson Acquisition Broadens the Buyer Universe
Kirin Holdings' purchase of Jamieson Wellness for approximately $1.8 billion extends this trend beyond US CPG and domestic private equity. Kirin, a Japanese beverage and pharmaceutical conglomerate, has been systematically expanding into functional health through its ownership of supplements and probiotics assets across the Asia-Pacific region. Jamieson gives Kirin a North American platform with strong brand recognition, retail distribution depth, and a loyal consumer base in Canada.
The strategic logic is straightforward. Asia-Pacific consumers are among the fastest-growing adopters of dietary supplements globally, and established Western brands carry an aspirational quality that domestic alternatives often don't. Kirin is effectively buying access to that brand equity and distribution infrastructure simultaneously.
What this means practically is that the acquirer base for well-positioned supplement brands is now genuinely global. You're not just competing to attract a US strategic buyer or a New York-based PE firm. You're competing for attention from Tokyo, Seoul, Singapore, and beyond. That expands the potential exit universe, but it also raises the floor on what a credible acquisition candidate looks like.
What This Means for Mid-Sized Sports Nutrition and Wellness Brands
If you're running a mid-sized supplement or sports nutrition brand, the consolidation wave is compressing your window as an independent operator. That's not necessarily a threat, but it is a forcing function. The window between "interesting startup" and "strategic acquisition target" is narrowing, and the criteria for crossing that threshold are sharpening.
Three variables are now driving supplement valuations above anything else:
- Clinical substantiation. Brands backed by published research, third-party testing, or professional endorsement ecosystems command higher multiples. Marketing claims without evidence are a liability in due diligence, not an asset.
- Proprietary consumer data. Direct-to-consumer infrastructure, subscription models, and first-party health data give acquirers something they can't easily replicate. Brands that sell exclusively through retail are easier to replicate and harder to value.
- Scale with category focus. Trying to cover every supplement category is a signal of strategic indecision. The most attractive acquisition targets own a defensible segment deeply, whether that's protein, gut health, sleep, or performance recovery.
Revenue alone doesn't move the multiple anymore. A brand doing $50 million in revenue with strong subscription retention, clinical backing, and a coherent consumer identity is worth significantly more to a strategic buyer than a brand doing $80 million through fragmented retail and promotional pricing.
This dynamic mirrors what's happening in the broader fitness industry. As fitness brands navigate GLP-1 tailwinds and digital health convergence, the brands gaining institutional traction are the ones with proprietary consumer relationships and data infrastructure, not just product volume.
Brain Health: The Next Acquisition Frontier
If you're trying to identify where the next wave of M&A activity lands, brain health is the category with the most obvious gap between consumer demand and clinical validation. The global brain health supplement market was valued at $7.6 billion in 2021 and is projected to reach $15.59 billion by 2030, representing a compound annual growth rate that most consumer categories can't match.
The challenge is that the category is still crowded with under-substantiated products. Most "nootropic" and cognitive support supplements on the market are trading on trend appeal rather than clinical evidence. That creates an opening: the brand or brands that build a credible, evidence-backed position in brain health before the consolidation cycle arrives in that category will be positioned for the kind of acquisition premium that Thorne just achieved.
Strategics and PE firms are already watching this segment closely. The pattern they're looking for is familiar: rising consumer intent, low current clinical rigor, and a market structure that's still fragmented enough to build a defensible leader position before prices get bid up. Brain health checks all three boxes right now.
For brands already operating in adjacent areas like sports performance or gut health, brain health represents a credible adjacency move. The consumer overlap is real, and the clinical investment required to differentiate in this category is achievable for brands that have already built research infrastructure.
The Strategic Takeaway for Brand Builders
The supplement sector's maturation into a billion-dollar M&A arena is not a temporary spike. The deals done in 2026 reflect structural forces: an aging global population investing in preventive health, post-pandemic normalization of supplement use across demographics, and institutional capital recognizing that recurring consumer health spending is as defensible as almost any other consumer category.
For anyone building in this space, the roadmap is clearer than it's been in a decade. Build clinical credibility early. Invest in direct-to-consumer infrastructure that generates first-party data. Own a category deeply rather than spreading across many. And understand that your exit value will be determined not by your top-line revenue but by the quality of the consumer relationship you've built and the evidence base behind your products.
The brands that position thoughtfully now are the ones that will show up on acquisition shortlists when the next wave of deals closes. The ones that don't will find themselves on the wrong side of the market bifurcation that Nestlé's divestiture made explicit. The window to choose which side you're on is still open, but it's narrowing faster than most independent operators realize.
Understanding what drives premium valuations in adjacent categories is equally important context. Planet Fitness's $360M revenue playbook and the patterns behind the $24 billion strength equipment opportunity share the same structural logic: recurring revenue, branded consumer relationships, and proprietary operating infrastructure command the multiples that commodity volume never will.